Cannabis Advocates Challenge DEA Rescheduling Process Integrity
Industry groups question fairness of federal marijuana rescheduling proceedings as regulatory uncertainty weighs on sector valuations.
Cannabis advocacy groups are mounting organized opposition to what they characterize as procedural irregularities in the DEA's ongoing marijuana rescheduling review process. The protests highlight growing frustration within the industry over the pace and transparency of federal regulatory reform efforts that could reshape the $30 billion U.S. cannabis market.
The demonstrations come as the cannabis sector faces mounting pressure from prolonged federal limbo. Major operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) continue trading at depressed valuations despite strong operational performance, largely due to regulatory uncertainty and limited institutional investment access. The industry's aggregate market capitalization remains roughly 70% below 2021 peaks.
Advocates argue the current rescheduling framework lacks adequate stakeholder input and transparency, potentially undermining the legitimacy of any eventual decision. This procedural challenge adds another layer of complexity to an already convoluted federal reform process that has stretched across multiple presidential administrations. The Biden administration's initial support for rescheduling has yet to translate into concrete regulatory action.
The protests underscore broader industry concerns about federal agencies' approach to cannabis policy reform. While individual states continue expanding legal markets—with adult-use programs now operating in 24 states—federal prohibition maintains banking restrictions, tax burdens, and interstate commerce barriers that constrain sector growth. These regulatory headwinds particularly impact multi-state operators seeking to optimize supply chains and access traditional capital markets.
Investor sentiment remains cautious as the industry awaits clarity on federal reform timing and structure. Any perceived bias or procedural flaws in the rescheduling process could delay implementation further, extending the regulatory uncertainty that has kept institutional investors largely sidelined. The sector's path to broader legitimacy and improved valuations increasingly depends on transparent, credible federal policy development that addresses stakeholder concerns while advancing meaningful reform.